✦ LIBER ✦

A phase 1/pilot study of radiofrequency ablation for the treatment of recurrent pediatric solid tumors

✍ Scribed by Fredric A. Hoffer; Najat C. Daw; Xiaoping Xiong; Doralina Anghelescu; Matthew Krasin; Xiaowei Yan; Andrew M. Davidoff; Wayne L. Furman; Carlos Rodriguez-Galindo; Sheri L. Spunt

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 385 KB
Volume: 115
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24158

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 1 study of an oxaliplatin and etop

Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors

✍ Lisa M. McGregor; Sheri L. Spunt; Victor M. Santana; Clinton F. Stewart; Deborah 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB 👁 1 views

Pilot study of topotecan and high-dose c

Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors

✍ Kushner, Brian H. ;Kramer, Kim ;Meyers, Paul A. ;Wollner, Norma ;Cheung, Nai-Kon 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

Phase I study of a 120-hour continuous i

Phase I study of a 120-hour continuous intravenous infusion of 5-fluorouracil in pediatric patients with recurrent solid tumors: A pediatric oncology group study

✍ Green, Daniel M. ;Krischer, Jeffrey P. ;Bell, Beverly ;Brecher, Martin L. ;Cushi 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB

## Abstract To determine the maximum tolerated dose of 5‐fluorouracil administered as a 120‐hour continuous intravenous infusion to pediatric patients, we performed a phase I study using a starting dosage of 900 mg/m^2^/day. The maximum tolerated dosage (MTD) was 1,100 mg/m^2^/day. At this dosage l

5-fluorouracil and cis-platinum in the t

5-fluorouracil and cis-platinum in the treatment of refractory solid tumors: A pediatric oncology group phase I — II study

✍ Land, Vita J. ;Dyment, Paul G. ;Starling, Kenneth ;Strandjord, Sarah E. ;Chan, R 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB

## Abstract Eleven patients with osteogenic sarcoma (9), Hodgkin disease (1), and mesenchymal sarcoma (1), were treated with 5‐fluorouracil (5‐FU) and cisplatin (DDP). Myelosuppression and vomiting of variable degrees occurred in all. No responses were seen.

A phase II study of homoharringtonine fo

A phase II study of homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: A pediatric oncology group study

✍ Bell, Beverly A. ;Chang, Myron N. ;Weinstein, Howard J. 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB

## Abstract ## Background Homoharringtonine (HHT) is a plant alkaloid that is derived from a Chinese evergreen tree. Its mechanism of action is thought to be by inhibition of protein, DNA, and RNA synthesis by inhibition of chain initiation. The treatment of acute myelogenous leukemia (AML) in chi

Phase II investigation of docetaxel in p

Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors : A report from the Children's Oncology Group

✍ Ted Zwerdling; Mark Krailo; Philip Monteleone; Rebecca Byrd; Judith Sato; Rose D 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

## Abstract ## BACKGROUND Docetaxel, which is an antitubulin agent, has demonstrable activity against murine and human tumors. The current study was designed to determine response rates to docetaxel in various strata of recurrent solid tumors of childhood and to assess toxicity in a group of patie